Lonza Group AG in 2 stories
The narratives LONN.SW currently appears in, with its side and exposure in each.
Bull side
2 stories- Drug Manufacturing De-Risks From China
LONN.SW in “Drug Manufacturing De-Risks From China”
FadingExposure: not rated yetWestern drugmakers are paying for non-Chinese capacity before procurement restrictions become binding.
Lonza is a leading Western biologics manufacturer positioned to capture programs moved away from Chinese suppliers.
- The Patent Cliff Sparks a Biotech Land Grab
LONN.SW in “The Patent Cliff Sparks a Biotech Land Grab”
FadingExposure: not rated yetLarge drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.
Lonza benefits as acquired biologics and advanced therapies require complex development and outsourced manufacturing capacity.
Bear side
0 storiesNo bear-side stories for LONN.SW yet.